Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Q4 2025 value amounting to $347.4 million.

  • Arrowhead Pharmaceuticals' Total Current Liabilities rose 27055.5% to $347.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $347.4 million, marking a year-over-year increase of 27055.5%. This contributed to the annual value of $195.5 million for FY2025, which is 8948.41% up from last year.
  • According to the latest figures from Q4 2025, Arrowhead Pharmaceuticals' Total Current Liabilities is $347.4 million, which was up 27055.5% from $195.5 million recorded in Q3 2025.
  • In the past 5 years, Arrowhead Pharmaceuticals' Total Current Liabilities registered a high of $347.4 million during Q4 2025, and its lowest value of $63.7 million during Q4 2023.
  • Its 5-year average for Total Current Liabilities is $140.9 million, with a median of $132.6 million in 2021.
  • In the last 5 years, Arrowhead Pharmaceuticals' Total Current Liabilities soared by 44607.48% in 2021 and then plummeted by 4777.19% in 2023.
  • Arrowhead Pharmaceuticals' Total Current Liabilities (Quarter) stood at $137.0 million in 2021, then dropped by 10.96% to $122.0 million in 2022, then tumbled by 47.77% to $63.7 million in 2023, then soared by 47.13% to $93.8 million in 2024, then surged by 270.56% to $347.4 million in 2025.
  • Its Total Current Liabilities was $347.4 million in Q4 2025, compared to $195.5 million in Q3 2025 and $194.5 million in Q2 2025.